#biotechnology - Techseriesinsight

May 1, 2025
PRNewswire
Biotechnology

Sapience Therapeutics Announces Oral Presentation at the Upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Featuring Lucicebtide Phase 2 Results

Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced that data from...

April 15, 2025
PRNewswire
Biotechnology

ThirtyFiveBio Closes Bridge Round of Financing Highlighted by Strategic New Investment from AbbVie Ventures

ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today announced the closing of a...

April 15, 2025
PRNewswire
Biotechnology

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive results from the 4-week multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial...

April 10, 2025
PRNewswire
Biotechnology

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a...

April 4, 2025
PRNewswire
Biotechnology

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company’s executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an accomplished physician-scientist...

April 1, 2025
PRNewswire
Biotechnology

Data Showcasing ALZpath’s Proprietary pTau217 Antibody at AD/PD™ 2025 Demonstrates High Rate of Reliability and Scalability for Alzheimer’s Disease Research and Diagnosis

ALZpath, Inc. (ALZpath), a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced the inclusion of data from evaluation of blood testing platforms utilizing its...

March 26, 2025
PRNewswire
Data Management Platform

DATAcc by DiMe Releases Resources to Build the Business Case for Digital Endpoints

Today, the Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe), the global home for digital health measures development, released a suite of resources designed to...

March 26, 2025
PRNewswire
Biotechnology

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a...

March 25, 2025
PRNewswire
Biotechnology

AngeoPro Yeast Protein Wins 2025 World Best Ingredient Innovation Award, Pioneering a New Era of Sustainable Protein

The 2025 World Food Innovation Awards, hosted by FoodBev, took place on March 17, 2025 at the IFE International Food and Beverage Exhibition’s “Trend and Innovation Platform” in London, UK. AngeoPro Yeast...

March 25, 2025
PRNewswire
Biotechnology

Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a letter of intent...